Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 430

1.
2.

High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.

Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, Liu JN, Drew BJ.

Crit Care Med. 2012 Feb;40(2):394-9. doi: 10.1097/CCM.0b013e318232db4a.

PMID:
22001585
3.

Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.

Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ.

Circ Cardiovasc Qual Outcomes. 2014 May;7(3):381-90. doi: 10.1161/CIRCOUTCOMES.113.000651. Epub 2014 May 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):981.

4.

Prevalence and determinants of QT interval prolongation in medical inpatients.

Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, Aujesky D.

Intern Med J. 2012 Aug;42(8):933-40. doi: 10.1111/j.1445-5994.2011.02447.x.

PMID:
21299787
5.

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.

Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM; REPOSI Investigators..

Drugs Aging. 2016 Jan;33(1):53-61. doi: 10.1007/s40266-015-0337-y.

PMID:
26693921
6.

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.

Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87. doi: 10.1161/CIRCOUTCOMES.113.000152. Epub 2013 May 28. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e57.

7.

QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.

Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE.

Curr Med Res Opin. 2013 Dec;29(12):1719-26. doi: 10.1185/03007995.2013.840568. Epub 2013 Sep 23. Review.

PMID:
24020938
8.

Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.

Freeman BD, Dixon DJ, Coopersmith CM, Zehnbauer BA, Buchman TG.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):971-81. doi: 10.1002/pds.1637.

9.

Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.

Othong R, Devlin JJ, Kazzi ZN.

Clin Toxicol (Phila). 2015 May;53(4):204-9. doi: 10.3109/15563650.2015.1013547. Epub 2015 Feb 23.

PMID:
25706450
10.

Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?

Mayet S, Gossop M, Lintzeris N, Markides V, Strang J.

Drug Alcohol Rev. 2011 Jul;30(4):388-96. doi: 10.1111/j.1465-3362.2010.00237.x. Epub 2010 Sep 6.

PMID:
21355918
11.

QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.

Perrin-Terrin A, Pathak A, Lapeyre-Mestre M.

Fundam Clin Pharmacol. 2011 Aug;25(4):503-10. doi: 10.1111/j.1472-8206.2010.00871.x. Epub 2010 Sep 6.

PMID:
20825488
12.

Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.

Jardin CG, Putney D, Michaud S.

Ann Pharmacother. 2014 Feb;48(2):196-202. doi: 10.1177/1060028013512614. Epub 2013 Dec 3.

PMID:
24301687
13.

[Drug induced QT prolongation].

Altmann D, Eggmann U, Ammann P.

Wien Klin Wochenschr. 2008;120(5-6):128-35. doi: 10.1007/s00508-008-0940-6. Review. German.

PMID:
18365152
14.

Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?

Samuelov-Kinori L, Kinori M, Kogan Y, Swartzon M, Shalev H, Guy D, Ferenidou F, Mashav N, Sadeh B, Atzmony L, Kliuk-Ben-Basat O, Steinvil A, Justo D.

J Electrocardiol. 2009 Jul-Aug;42(4):353-357.e1. doi: 10.1016/j.jelectrocard.2009.01.005. Epub 2009 Mar 3.

PMID:
19261294
15.

Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP.

Drug Saf. 2012 Jul 1;35(7):547-53. doi: 10.2165/11599960-000000000-00000.

PMID:
22702639
16.

Acquired long QT syndrome: frequency, onset, and risk factors in intensive care patients.

Kozik TM, Wung SF.

Crit Care Nurse. 2012 Oct;32(5):32-41. doi: 10.4037/ccn2012900.

17.

Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.

Darbar D, Kimbrough J, Jawaid A, McCray R, Ritchie MD, Roden DM.

J Am Coll Cardiol. 2008 Feb 26;51(8):836-42. doi: 10.1016/j.jacc.2007.09.066.

18.

Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.

Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, Dimopoulos NP, Filippatos GS, Sideris A, Kardaras F.

Clin Res Cardiol. 2009 Apr;98(4):208-12. doi: 10.1007/s00392-008-0741-y. Epub 2008 Nov 24.

PMID:
19031039
19.

Association between a prolonged corrected QT interval and outcomes in patients in a medical Intensive Care Unit.

George TK, Chase D, Peter JV, Satyendra S, Kavitha R, George LR, Thomas VV.

Indian J Crit Care Med. 2015 Jun;19(6):326-32. doi: 10.4103/0972-5229.158271.

20.

Use of QT-prolonging medications in US emergency departments, 1995-2009.

Tay KY, Ewald MB, Bourgeois FT.

Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):9-17. doi: 10.1002/pds.3455. Epub 2013 May 21.

PMID:
23696066

Supplemental Content

Support Center